CD274 and non-small cell lung carcinoma: Consistent with recent studies that showed that PD-L1 tumor proportion score (TPS) does not necessarily predict the response to ICB therapy (Carbone et al, 2017; Shen & Zhao, 2018; Lu et al, 2019), the analysis of PD-L1 expression in tumor cells, which was obtained with the 22C3 clone on the Dako Autostainer Link 48 platform, showed that PD-L1 TPS did not correlate with ORR, OS, or PFS in our NSCLC cohort (TPS < 1%; 22.7% ORR, TPS 1–49%; 14.3%, and TPS ≤ 50%; 38.2%) (P = 0.071, Fig S4A–C and Table 2).